Skip to main content
An official website of the United States government

Cancer Immunoprevention Network (CIP-Net)

Wildtype and frameshift mutant Asxl1 mRNA detected by in situ hybridization using RNAScope technology in organoids derived from a mismatch repair-deficient mouse intestinal tumor.

The Cancer Immunoprevention Network (CIP-Net) supports the development of approaches that leverage the immune system to prevent cancers. Research in CIP-Net is advancing a deeper understanding of basic mechanisms of immunoprevention and promoting the discovery of novel immunoprevention strategies. Both the National Cancer Institute Division of Cancer Prevention and the Division of Cancer Biology support researchers in this network.

On This Page

  • All Heading 2s will automatically be pulled in to this list.
  • Do not edit the content on this template.

About the Cancer Immunoprevention Network

CIP-Net supports projects from basic through translational preclinical research with an emphasis on exploring the biology of early malignancy and addressing the research gap between immunoprevention and immunotherapy.

The overall research objectives of the Network are to:

  • Discover novel immunoprevention pathways and targets
  • Elucidate immune responses to the earliest stages of carcinogenesis
  • Preclinical development and testing of interventions (agents/vaccines)
  • Investigate mechanisms of efficacy and potential side-effects of precision cancer prevention-interception strategies
  • Develop and optimize immunoprevention models
  • Define immune mechanisms of preventive cancer vaccines and immunomodulatory agents

Candidate agents and vaccines that emerge from CIP-Net research may move forward to the PREVENT program for further preclinical development towards clinical trials.

Grantee Details

PI Name PI Organization Title Grant Number Program Official
Kober, Kord Michael

University Of California, San Francisco
United States

 An Investigation of the Molecular Mechanisms for and Prediction of the Severity of Cancer Chemotherapy-Related Fatigue Using a Multi-staged Integrated Omics Approach 5R37CA233774-07 Brandy Heckman-Stoddard, Ph.D., M.P.H.
Kolb, Noah Allan

University Of Vermont & St Agric College
United States

 Remote Monitoring of Management of Chemotherapy induced Peripheral Neuropathy 5R01CA247517-05 Brennan Streck, Ph.D., RN, M.P.H.
Kolb, Noah Allan

University Of Vermont & St Agric College
United States

 Remote Monitoring of Management of Chemotherapy induced Peripheral Neuropathy 5R01CA247517-05 Brennan Streck, Ph.D., RN, M.P.H.
Kong, Mei

University Of California-Irvine
United States

 Using dietary glutamine supplementation for melanoma prevention and targeted therapy 5R01CA244360-05 Gabriela Riscuta, M.D., CNS
Kooperberg, Charles L

Fred Hutchinson Cancer Center
United States

 Statistics and Data Management Center (SDMC) for the NCI Cancer Screening Research Network (CSRN) 5UG1CA287013-02 Elyse LeeVan, M.D., M.P.H.
Kresty, Laura A

University Of Michigan At Ann Arbor
United States

 Developing Natural Products to Target IL-8 Signaling and Intercept Progression of Barrett’s Esophagus to Esophageal Adenocarcinoma 1UG3CA299397-01 Altaf Mohammed, Ph.D.
Krist, Alexander H

Virginia Commonwealth University
United States

 Virginia Cancer Screening Research Network Access Hub (Virginia CSRN Hub) 3UG1CA287017-02S1 Elyse LeeVan, M.D., M.P.H.
Kroetz, Deanna L

Ohio State University
United States

 Sphingolipid Signaling and Chemotherapy-Induced Peripheral Neurotoxicity 5R01CA261068-06 Rachel Altshuler, Ph.D.
Kroetz, Deanna L

Ohio State University
United States

 Sphingolipid Signaling and Chemotherapy-Induced Peripheral Neurotoxicity 5R01CA261068-06 Rachel Altshuler, Ph.D.
Kuhn, Peter

University Of Southern California
United States

 Multi-modal Liquid Biopsy Early Assessment of Breast Cancer, Pancreatic Cancer, and Multiple Myeloma 4U01CA285013-03 Nicholas Hodges, Ph.D.
Kumar, Nagi B.

H. Lee Moffitt Cancer Ctr & Res Inst
United States

 Phase II Clinical trial of GTC in Men on Active Surveillance 5R01CA235032-06 Howard L. Parnes, M.D.
Labaer, Joshua

Arizona State University-Tempe Campus
United States

 High-throughput immunoproteomics for cancer biomarker discovery 5U2CCA271903-04 Christos Patriotis, Ph.D., M.Sc.
Labaer, Joshua

Arizona State University-Tempe Campus
United States

 Multiplex In-Solution Protein Array (MISPA) for high throughput, quantitative, early profiling of pathogen-induced head and neck 5R33CA281802-03 Wendy Wang, Ph.D., M.Sc.
Lampe, Paul D.

Fred Hutchinson Cancer Center
United States

 Autoantibodies to tumor-derived neoepitopes as biomarkers and immunoPET agents for the early detection of small cell lung cancer 5R01CA281801-03 Guillermo Marquez, Ph.D.
Langel, Stephanie N.

Case Western Reserve University
United States

 Antibody bound bacteria during HPV infection and cervical dysplasia 3R21CA289927-02S1 Goli Samimi, Ph.D., M.P.H.

Program Contact(s)

Altaf Mohammed, Ph.D.
NCI DCP Chemopreventive Agent Development Research Group
Email: altaf.mohammed@nih.gov
Phone: 240-276-6082
Room: 5E554